Clinical Trials on Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alte in Poland

Total 34 results

EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification | Lung Adenocarcinoma Stage IIIB/IV

Spain, Taiwan, United States, Korea, Republic of, Netherlands, Israel, Belgium, Italy, China, France, Germany, Japan, Poland, Austria, Switzerland
Rain Oncology Inc

Terminated

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN)

NSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB Fusion

United States, Canada, Hong Kong
Southwest Oncology Group
Patient-Centered Outcomes Research Institute; National Cancer Institute (NCI)

Completed

S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) (TrACER)

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Febrile Neutropenia | Stage 0 Breast Cancer | Stage IV Non-Small Cell Lung Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast... and other conditions

United States, Puerto Rico
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Advanced Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma

United States
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
OHSU Knight Cancer Institute
AstraZeneca; Oregon Health and Science University

Completed

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
Taiho Oncology, Inc.

Recruiting

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3)

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

United States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
NovaRx Corporation

Completed

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)

Lung Neoplasm | Carcinoma Non-small Cell Lung Cancer Stage IIIA | Carcinoma Non-small Cell Lung Cancer Stage IIIB | Carcinoma Non-small Cell Lung Cancer Stage IV

United States, Hungary, United Kingdom, Netherlands, Canada, India, Poland, Serbia
Synta Pharmaceuticals Corp.

Terminated

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer (GALAXY)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV

United States, Belgium, Bosnia and Herzegovina, Canada, Croatia, Czech Republic, Germany, Poland, Romania, Russian Federation, Serbia, Spain, United Kingdom
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL797 in Adults With Solid Tumors

Advanced Breast Cancer | NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Recurrent Breast Cancer | TNBC - Triple-Negative Breast Cancer | Relapsed Cancer | NSCLC, Recurrent | Recurrent... and other conditions

United States
AstraZeneca

Completed

Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment. (SELECT-2)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Poland, France, Germany, Brazil, Hungary, Netherlands, Bulgaria
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Metastatic Renal Cell Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Metastatic Melanoma | Fallopian Tube Carcinoma | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal... and other conditions

United States
AstraZeneca

Active, not recruiting

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Canada, France, Italy, Spain, United Kingdom, Belgium, Poland, Brazil, Germany, Hungary, Peru, Russian Federation, Turkey, Australia, Chile, Austria, Netherlands, Portugal, Israel, Mexico, Romania, Sweden, Ukraine, Bulgaria, Argenti...
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Stage IIIB Non-Small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy

Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)

Recruiting

Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Advanced Lung Non-Small Cell Carcinoma | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7

United States
National Cancer Institute (NCI)

Completed

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

Stage III Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Locally Advanced Lung Non-Small Cell Carcinoma

United States
iTeos Belgium SA

Recruiting

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Metastatic NSCLC | Stage III NSCLC

United States, Belgium, Spain, Switzerland, Italy, France, Canada, Poland, Czechia
National Cancer Institute (NCI)

Active, not recruiting

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8

United States, Canada, Guam
Peregrine Pharmaceuticals

Completed

Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer (SUNRISE)

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Non-Small-Cell Lung Carcinoma | Non-Small-Cell Lung Cancer Stage IIIB | Non-Small-Cell Lung Cancer Stage IV | Non-Small-Cell Lung Cancer Metastatic

United States, Australia, Belgium, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Romania, Russian Federation, Spain, Taiwan, Ukraine
National Cancer Institute (NCI)

Recruiting

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Medical Research Foundation, Oregon; ATS... and other collaborators

Active, not recruiting

Decision Aid for the Improvement of Decision-Making in Patients With Non-small Cell Lung Cancer

Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8

United States
Synta Pharmaceuticals Corp.

Terminated

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC (Galaxy 2)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV | Non-Small-Cell Lung Adenocarcinoma

United States, France, Spain, Netherlands, Czech Republic, Serbia, Romania, Germany, Belgium, Italy, Hungary, United Kingdom, Canada, Poland, Bosnia and Herzegovina, Austria, Slovenia, Croatia, Russian Federation, Ukraine
Taiho Oncology, Inc.

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

United States, Japan, Spain, France, Australia, Italy, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial

Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Locally Advanced Lung Non-Small Cell Carcinoma | Locally Recurrent Lung Non-Small Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative

Lung Adenocarcinoma | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Lung Adenosquamous Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Malignant Solid Neoplasm | Acute Myeloid Leukemia | Multiple Myeloma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer... and other conditions

United States, Puerto Rico
Fog Pharmaceuticals, Inc.

Recruiting

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Cancer | Gastric Cancer | Colorectal Cancer | Solid Tumor | Metastatic Cancer | Adenomatous Polyposis Coli | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Carcinoma | Locally Advanced Solid Tumor | Non-small Cell Lung Cancer Stage IIIB | Gastroesophageal-junction Cancer | Non-Small... and other conditions

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Collecting Tumor Samples From Patients With Gynecological Tumors

Melanoma | Malignant Mesothelioma | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Serous Cystadenocarcinoma | Gestational Trophoblastic Tumor | Cervical Adenocarcinoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer

Lung Adenocarcinoma | Minimally Invasive Lung Adenocarcinoma | Malignant Pleural Effusion | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Malignant Pericardial Effusion | Lung Adenosquamous Carcinoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Clear Cell Renal Cell Carcinoma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent... and other conditions

United States, Germany, Italy
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States

Clinical Trials on Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alte in Poland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations